|Bid||3,800.00 x 51000|
|Ask||3,940.00 x 53800|
|Day's Range||3,793.00 - 3,860.00|
|52 Week Range||3,603.50 - 5,331.00|
|PE Ratio (TTM)||51.34|
|Dividend & Yield||0.26 (0.51%)|
|1y Target Est||N/A|
Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Shire was the seventh-largest holding in Cooperman's Omega Advisors’ portfolio in 2Q17, representing nearly 3.5% of total holdings.
Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Shire Plc a score of 47. Our analysis is based on comparing Shire Plc with the following peers – GlaxoSmithKline plc, Hikma Pharmaceuticals Plc, AstraZeneca PLC and Pfizer Inc. (GSK-GB, HIK-GB, AZN-GB and PFE-SE). Investment Outlook Shire Plc has a fundamental score of 47 and has a ... Read more (Read more...)